177 related articles for article (PubMed ID: 15758755)
1. Increased warning time with darifenacin: a new concept in the management of urinary urgency.
Cardozo L; Dixon A
J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB.
Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F
Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
[TBL] [Abstract][Full Text] [Related]
4. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.
Haab F; Stewart L; Dwyer P
Eur Urol; 2004 Apr; 45(4):420-9; discussion 429. PubMed ID: 15041104
[TBL] [Abstract][Full Text] [Related]
5. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.
Foote J; Glavind K; Kralidis G; Wyndaele JJ
Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219
[TBL] [Abstract][Full Text] [Related]
6. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
Steers W; Corcos J; Foote J; Kralidis G
BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD
BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437
[TBL] [Abstract][Full Text] [Related]
8. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
Hill S; Khullar V; Wyndaele JJ; Lheritier K;
Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217
[TBL] [Abstract][Full Text] [Related]
9. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.
Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A
Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of health-related quality of life outcomes with darifenacin.
Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers.
Kay GG; Wesnes KA
BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
13. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
14. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
Olshansky B; Ebinger U; Brum J; Egermark M; Viegas A; Rekeda L
J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):241-51. PubMed ID: 18832343
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
17. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U
Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723
[TBL] [Abstract][Full Text] [Related]
18. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
19. Assessment of cognitive function of the elderly population: effects of darifenacin.
Lipton RB; Kolodner K; Wesnes K
J Urol; 2005 Feb; 173(2):493-8. PubMed ID: 15643227
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.
Kay G; Crook T; Rekeda L; Lima R; Ebinger U; Arguinzoniz M; Steel M
Eur Urol; 2006 Aug; 50(2):317-26. PubMed ID: 16687205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
